Aldoxorubicin

Generic Name: Aldoxorubicin

Drug Type: Small Molecule

Chemical Formula: C_₃₇H_₄₂N_₄O_₁₃

CAS Number: 1361644-26-9

Unique Ingredient Identifier: C28MV4IM0B

Background: Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

Indication: Investigated for use/treatment in solid tumors.

Clinical Trials

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

Conditions: Sarcoma

First Posted Date: 2015-10-07

Last Posted Date: 2015-10-22

Lead Sponsor: CytRx

Registration Number: NCT02570412

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors

Phase 1

Completed

Conditions: Metastatic Solid Tumors

Interventions: Drug: aldoxorubicin
Drug: gemcitabine

First Posted Date: 2014-09-10

Last Posted Date: 2022-02-10

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 30

Registration Number: NCT02235688

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Interventions: Drug: 170 mg/m2 aldoxorubicin
Drug: 250 mg/m2 aldoxorubicin

First Posted Date: 2014-09-10

Last Posted Date: 2024-05-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 70

Registration Number: NCT02235701

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Phase 2

Completed

Conditions: Metastatic Small Cell Lung Cancer

Interventions: Drug: Aldoxorubicin
Drug: Topotecan

First Posted Date: 2014-07-25

Last Posted Date: 2024-06-25

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 135

Registration Number: NCT02200757

Locations: 🇺🇸
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
🇺🇸
Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸
Oncology Hermatology Care, Inc., Cincinnati, Ohio, United States

and more 26 locations

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Phase 3

Completed

Conditions: Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

Interventions: Drug: Aldoxorubicin
Drug: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)

First Posted Date: 2014-01-30

Last Posted Date: 2024-06-13

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 433

Registration Number: NCT02049905

Locations: 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇺🇸
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States

and more 70 locations

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

Phase 2

Completed

Conditions: HIV Positive
Kaposi's Sarcoma
AIDS

Interventions: Drug: 150 mg/m2 aldoxorubicin
Drug: 50 mg/m2 aldoxorubicin
Drug: 100 mg/m2 aldoxorubicin

First Posted Date: 2014-01-07

Last Posted Date: 2024-06-11

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 15

Registration Number: NCT02029430

Locations: 🇺🇸
Louisiana State University Health Science Center, New Orleans, Louisiana, United States

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: 350 mg/m2 aldoxorubicin
Drug: 250 mg/m2 aldoxorubicin

First Posted Date: 2013-12-18

Last Posted Date: 2024-05-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 28

Registration Number: NCT02014844

Locations: 🇺🇸
Ochsner Health System, New Orleans, Louisiana, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
Texas Oncology-Austin Midtown, Austin, Texas, United States

and more 1 locations

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: aldoxorubicin

First Posted Date: 2012-10-15

Last Posted Date: 2022-02-10

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 18

Registration Number: NCT01706835

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: aldoxorubicin

First Posted Date: 2012-08-28

Last Posted Date: 2022-02-10

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 15

Registration Number: NCT01673438

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: INNO-206

First Posted Date: 2012-04-19

Last Posted Date: 2024-06-06

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 15

Registration Number: NCT01580397

Locations: 🇺🇸
Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸
Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders, Milwaukee, Wisconsin, United States
🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy